Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF‐06826647: A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalation Study

Selective inhibition of tyrosine kinase 2 (TYK2) may offer therapeutic promise in inflammatory conditions, with its role in downstream pro‐inflammatory cytokine signaling. In this first‐in‐human study, we evaluated the safety, tolerability, and pharmacokinetics (PK) of a novel TYK2 inhibitor, PF‐068...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Ravi Shankar P., Pradhan, Vivek, Roberts, Erika S., Scaramozza, Matthew, Kieras, Elizabeth, Gale, Jeremy D., Peeva, Elena, Vincent, Michael S., Banerjee, Anindita, Fensome, Andrew, Dowty, Martin E., Winkle, Peter, Tehlirian, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993274/
https://www.ncbi.nlm.nih.gov/pubmed/33290616
http://dx.doi.org/10.1111/cts.12929

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993274/
https://www.ncbi.nlm.nih.gov/pubmed/33290616
http://dx.doi.org/10.1111/cts.12929

Ejemplares similares